Trials begin for PRO 140.
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic; D004311:Double-Blind Method; D015483:HIV Antibodies; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D019713:Receptors, CCR5 / Q000187:drug effects
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015483:HIV Antibodies; D019713:Receptors, CCR5; C420063:leronlimab